To the full analysis
Buyback calculator for Avalo Therapeutics
Avalo Therapeutics stock: key metrics
AVTXAvalo Therapeutics had an operating margin of −123,601.7% and a return on invested capital (ROIC) of −46.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | −10,142.4% | −12,676.4% | −12,674.7% |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | −614.6% | −1,394.6% | −1,428.5% |
| 2017 | 97.7% | 49.9% | 42.7% |
| 2018 | 59.2% | −214.5% | −218.5% |
| 2019 | 108.4% | −239.1% | −238.1% |
| 2020 | 95.5% | 0.0% | −947.9% |
| 2021 | 72.4% | −1,521.6% | −1,563.1% |
| 2022 | 81.0% | −207.4% | −230.8% |
| 2023 | 33.3% | −1,421.6% | −1,639.5% |
| 2024 | 183.0% | −15,535.6% | −7,965.8% |
| 2025 | 100.0% | −123,601.7% | −132,642.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | −100.0% | −97.8% | −100.0% |
| 2013 | 73.1% | no data | −100.0% |
| 2014 | 61.0% | no data | −100.0% |
| 2015 | −80.2% | −61.6% | −48.4% |
| 2016 | −100.0% | no data | −100.0% |
| 2017 | 42.6% | 104.4% | 27.5% |
| 2018 | −100.0% | −82.0% | −57.0% |
| 2019 | −76.6% | −71.7% | −44.5% |
| 2020 | −100.0% | 0.0% | −100.0% |
| 2021 | −100.0% | no data | −100.0% |
| 2022 | 200.0% | −76.3% | −100.0% |
| 2023 | −100.0% | no data | −100.0% |
| 2024 | −26.4% | −67.6% | −23.3% |
| 2025 | −94.2% | −46.6% | −67.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.